Related Experiment Video

Updated: Jun 21, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

Lipid lowering and aortic valve disease

Anders G Olsson1

  • 1Faculty of Health Sciences, Linköping University, Bromma, Sweden. andol@imv.liu.se

Current Atherosclerosis Reports
|August 12, 2009
PubMed

Insights

Lowering low-density lipoprotein cholesterol (LDL-C) may not significantly slow aortic stenosis (AS) progression, as indicated by recent trials. Further research is needed to determine the role of lipid-lowering therapies in managing AS.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials
  • Lipid Metabolism

Background:

  • Aortic stenosis (AS) shares early pathogenic similarities with atherosclerosis.
  • Previous studies suggested lipid lowering might slow AS progression.
  • Recent randomized trials have investigated this hypothesis.

Purpose of the Study:

  • To evaluate the effect of low-density lipoprotein cholesterol (LDL-C) lowering on the progression of aortic stenosis (AS).
  • To assess the clinical consequences of lipid-lowering interventions in patients with AS.

Main Methods:

  • Two randomized placebo-controlled trials (SALTIRE and SEAS) were conducted.
  • These studies investigated the impact of LDL-C reduction on AS progression.
  • The ASTRONOMER study is an ongoing trial examining rosuvastatin's effect on AS.

Main Results:

  • Both the SALTIRE and SEAS studies yielded neutral outcomes.
  • These results suggest that LDL-C lowering may not significantly impact AS progression.
  • The precise reasons for the neutral outcomes are under investigation.

Conclusions:

  • Current evidence does not support routine lipid-lowering therapy for slowing AS progression.
  • Potential factors influencing trial outcomes include study design and treatment specifics.
  • Further investigation, such as the ASTRONOMER study, is anticipated to clarify the role of statins in AS management.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...